GSK’s Stiefel to acquire psoriasis, eczema compound from Welichem

Psoriasis GlaxoSmithKline‘s (NYSE:GSK) dermatology subsidiary Stiefel is building up its drug pipeline with a deal in principal to acquire a skin treatment candidate from Welichem Biotech (TSX:W…
Read the full story: MedCity News